Kieran Leahy, general manager of Takeda in the Czech Republic and Slovakia, recounts how he has led the transformation of Takeda into a specialty care organization at the local level, and his priorities to successfully integrate Shire along this journey. Leahy also breaks down the market access challenges in the Czech Republic, especially for orphan drugs, and how the company navigates them, but is optimistic that new legislation will provide smoother access, whilst sharing his understanding of the Takeda-ism philosophy, and his priorities to continue driving Takeda’s transformation.
The cultures of [both Takeda and Shire], whilst different, shared a central pillar around which we could build the new organization: patient-centricity
